WSJ -- The halt in development by AstraZeneca PLC of its most advanced follow-up compound for respiratory syncytial virus infection, or RSV, might spur interest in a handful of earlier-stage projects. Developing a vaccine for the disease, which can be serious for infants and the elderly, remains a significant long-term goal for the biotech industry.
